- βEarly research suggests blocking IL-1Ξ² may prevent dangerous post-meal blood sugar crashes after weight loss surgery
- βA single injection of canakinumab could offer longer-lasting relief compared to daily medications
- βThe trial uses continuous glucose monitoring to objectively track results, reinforcing CGM's value in complex diabetes management
| Journal | BMJ open |
| Year | 2025 |
| Authors | Hepprich, Fischer, Cattaneo |
| PMID | 40425249 |
What Was Studied and Why It Matters
For many people who undergo bariatric (weight loss) surgery, the procedure brings life-changing benefits β but it can also trigger a frustrating and sometimes dangerous side effect called postbariatric hypoglycemia (PBH). This condition causes blood sugar to drop dangerously low after eating, leading to symptoms like shakiness, sweating, confusion, and even loss of consciousness. It affects quality of life significantly and currently has limited treatment options.
Researchers in Switzerland believe they may have found a new way to prevent these episodes β by targeting a specific protein in the body's immune system.
What the Researchers Found (So Far)
Scientists already knew that eating a meal triggers the release of a protein called IL-1Ξ² (interleukin-1 beta), which in turn tells the pancreas to release insulin. In people who have had bariatric surgery, this response can go into overdrive β the body releases too much insulin, causing blood sugar to crash.
An earlier small study showed that blocking this IL-1Ξ² signal with a drug called anakinra helped reduce post-meal blood sugar crashes. Now, the research team is testing a longer-acting version of this approach using a drug called canakinumab, which is given as a single injection under the skin and works for an extended period.
How the Trial Works
This is a carefully designed randomized, double-blind, placebo-controlled trial β the gold standard for medical research. That means:
- 62 adult patients who have had bariatric surgery and experience at least five low blood sugar episodes per week will be enrolled
- Half will receive a single injection of canakinumab; half will receive a harmless saltwater placebo
- Neither the patients nor researchers will know who received which treatment until the trial ends
- All participants will wear a continuous glucose monitor (CGM) for 28 days to track blood sugar patterns around the clock
- Participants will also keep a diary of their hypoglycemic episodes and symptoms
What This Means for Real Patients
If canakinumab proves effective, it could offer people struggling with post-surgery hypoglycemia a new treatment option that requires only a single injection β rather than daily medications or complex dietary restrictions. For patients who rely on CGM devices to track glucose levels (like those available through MDS Diabetes), this research also highlights just how essential continuous monitoring is in understanding and managing complex glucose patterns.
The trial is currently enrolling patients and results will be published in a peer-reviewed journal. It is registered internationally so findings will be openly available.
Bottom Line
This clinical trial is testing whether a single injection of an anti-inflammatory drug can reduce dangerous blood sugar drops that affect many bariatric surgery patients. By targeting the immune protein IL-1Ξ² β which triggers excessive insulin release after meals β researchers hope to offer a new, longer-lasting treatment option. Early evidence is promising, and the full trial results could meaningfully improve life for people living with this challenging post-surgery complication.